Compare Lamb Weston Holdings Inc (LW) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Pfizer Inc — how do they compare? Lamb Weston Holdings Inc trades at $52.79 (market cap $7.12B), while Pfizer Inc trades at $26.59 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 21.7× Lamb Weston Holdings Inc's market cap, and Pfizer Inc pays the higher dividend (6.36%). Which is the better fit depends on your goals.
| LW | PFE | |
|---|---|---|
Market Cap | $7.12B | $154.18B |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $28.56 |
52-Week Low | $38.48 | $23.60 |
Enterprise Value | $11.00B | $205.67B |
Dividend Yield | 2.93% | 6.36% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $52.27, up 0.42% today, with a bullish technical outlook and consistent earnings beats. The stock shows strong profitability with a 16.28% ROE and trades at a P/E of 25.13. Recent Q2 2026 results exceeded expectations with EPS of $0.87 versus $0.626 estimated. The company maintains a solid dividend yield with a recent $0.38 per share payout announced.
The outlook is positive given operational improvements and cost savings, though international headwinds and margin pressures pose risks. Analyst consensus is a 'Hold' with a $53.86 price target, indicating modest upside. Investors should weigh strong North American growth against geopolitical and cost challenges impacting international segments.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
